TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32162420
Drug: Buprenorphine and
Normalized name: Buprenorphine and Naloxone Buccal Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine and naloxone co‐formulation (1:1 ratio: buprenorphine 2 mg + naloxone 2 mg)
Study: 32162420
Drug: Pheniramine maleate
Normalized name: Pheniramine Maleate
DrugBank: Pheniramine (DB01620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pheniramine maleate (45.5 mg)
Study: 35839637
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS treatment (n = 29)
Study: 35839637
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (n = 27)
Study: 32924312
Drug: Dentin surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentin surface roughening/cervical groove preparation with round bur
Study: 32924312
Drug: Dentin surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentin surface roughening/cervical groove preparation with round bur plus flowable composite
Study: 32924312
Drug: No preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preparation (cavity cleaning only)
Study: 32142970
Drug: Watermelon puree
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watermelon puree (100% daily for 6 weeks)
Study: 36657324
Drug: Gemcitabine (G)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (G)
Study: 36267853
Drug: Jiuwei Zhenxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiuwei Zhenxin granules (single drug group)
Study: 36267853
Drug: Jiuwei Zhenxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiuwei Zhenxin granules and alprazolam (combination group)
Study: 36267853
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not explicitly mentioned, but implied as the combination treatment)
Study: 34553670
Drug: Intra-operative mapping
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-operative mapping of lymphatic leakage with peri-incisional methylene blue injection and clipping of lymphatics
Study: 33016169
Drug: Atraumatic Restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic Restorative Treatment and Hall Technique (ART‐HT)
Study: 33089408
Drug: 20-mg temozolomide
Normalized name: temozolomide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg temozolomide capsules (TOZ309)
Study: 33089408
Drug: 100-mg temozolomide
Normalized name: temozolomide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-mg temozolomide capsules (TOZ309)
Study: 33089408
Drug: Temodal® capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temodal® capsules
Study: 36415779
Drug: Concurrent application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent application of multiple techniques
Study: 33058277
Drug: Minimally enhanced
Normalized name: homatropine hydrobromide Ophthalmic Solution [Minims Homatropine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally enhanced treatment as usual (Control)
Study: 32781263
Drug: Sintilimab 200
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab 200 mg plus pemetrexed and platinum
Study: 35543938
Drug: Panlong needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panlong needling at Jiaji (EX‐B 2) combined with western medication
Study: 35543938
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication alone (levodopa and benserazide hydrochloride tablets)
Study: 32975296
Drug: Standard dressing,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dressing, elastic compression, and REAC TO-RPR treatment
Study: 32975296
Drug: Standard dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dressing and REAC TO-RPR treatment
Study: 35749710
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) at doses of 75-300 mg
Study: 33691576
Drug: CRMR treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRMR treatment (n = 19)
Study: 36347049
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment for 2 years
Study: 33127585
Drug: Possession of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Possession of an analgesic cream
Study: 33127585
Drug: Possession of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Possession of an anti-itch cream (pain-irrelevant control object)
Study: 34479631
Drug: Continued treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued treatment
Study: 32510984
Drug: Genotype-guided dosing
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided dosing group
Study: 32510984
Drug: Warfarin normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin normal sensitivity group (subgroup of genotype-guided dosing)
Study: 32510984
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard dosing)
Study: 36053658
Drug: Prescriptions
Normalized name: BODY PRESCRIPTIONS ANTIBACTERIAL HAND SANITIZER KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescriptions
Study: 33095999
Drug: Control (AE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (AE or tDCS administered alone)
Study: 35831626
Drug: PHS (spray)
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHS (spray) + tooth brushing
Study: 35831626
Drug: PHS (spray)
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHS (spray)
Study: 35194646
Drug: Manual physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual physical therapy including desensitization maneuvers of the central nervous system
Study: 35403841
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus platinum-based chemotherapy
Study: 35403841
Drug: Platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based chemotherapy alone
Study: 34857494
Drug: IV antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV antimicrobial treatment at home only
Study: 34857494
Drug: IV antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV antimicrobial treatment both at home and in hospital
Study: 34857494
Drug: IV antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV antimicrobial treatment in hospital only
Study: 32561663
Drug: Apalutamide (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalutamide (240 mg once daily)
Study: 32561663
Drug: Apalutamide (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalutamide (average daily dose reduced to 209 mg)
Study: 33059293
Drug: AMZ001 once
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMZ001 once daily (QD)
Study: 33059293
Drug: AMZ001 twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMZ001 twice daily (BID)
Study: 32124144
Drug: Integrated oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated oral language and listening comprehension intervention, delivered in small groups of 3 or 4, 4 days per week for 20 weeks
Study: 32620543
Drug: 20 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL/kg up to 1000 mL of normal saline (fluid bolus group)
Study: 32620543
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of normal saline (control group)
Study: 33993331
Drug: Conventional-dose CT
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose CT (CDCT, n = 1539)
Study: 33993331
Drug: Conventional-dose CT
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose CT (CDCT)
Study: 37074807
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g mannitol
Study: 37074807
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g mannitol
Study: 37074807
Drug: 150 g
Normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 g mannitol
Study: 33904329
Drug: Inoculation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inoculation with L. pseudotheobromae
Study: 33904329
Drug: Inoculation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inoculation with L. theobromae
Study: 32823839
Drug: Animal-Assisted Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal-Assisted Therapy (AAT) with a therapy dog
Study: 36169717
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clinical parameters and one-point MRD measurement
Study: 34088338
Drug: Credelio Plus®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Credelio Plus® (lotilaner and milbemycin oxime) administered orally at a dose rate of 20.0-41.5 mg/kg bodyweight once every 4 weeks for 3 months
Study: 34088338
Drug: Nexgard Spectra®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nexgard Spectra® (control product) administered as recommended once every 4 weeks for 3 months
Study: 34088338
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (Credelio Plus® and Nexgard Spectra®)
Study: 34743149
Drug: Nomogram based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomogram based on clinicopathologic variables (including ER+, PR+, HER2+ with Herceptin treatment, low ALNR) for predicting overall survival (OS)
Study: 32517663
Drug: Nonavalent HPV
Normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonavalent HPV vaccination (3 injections)
Study: 32517663
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections (NaCL 0.9%)
Study: 34153136
Drug: Telephone-based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based Cognitive Behaviour Therapy (T-CBT)
Study: 34153136
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual Cognitive Behaviour Therapy (TAU-CBT)
Study: 32668111
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg loading dose followed by 90 mg twice daily) plus Aspirin (300 to 325 mg on the first day followed by 75 to 100 mg daily)
Study: 32668111
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 to 325 mg on the first day followed by 75 to 100 mg daily)
Study: 38286485
Drug: Ticagrelor-aspirin
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor-aspirin
Study: 35473729
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg prednisolone for 1 week
Study: 35473729
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg prednisolone for 1 week
Study: 35473729
Drug: 1.125 mg
Normalized name: Ascorbic Acid/Calcium Pantothenate/Folic Acid/Kava/Lecithin/Niacin/St John's Wort/Thiamine 60 MG-5 MG-0.1 MG-100 MG-15 MG-10 MG-225 MG-1.125 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.125 mg dexamethasone per day for 1 week
Study: 35473729
Drug: 4.5 mg
Normalized name: phenol 14.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg dexamethasone per day for 1 week
Study: 32370640
Drug: Real-world data
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real-world data (RWD) patients treated with the same therapy as the control arm
Study: 33731270
Drug: Oral lefamulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lefamulin 600 mg every 12 h for 5 days
Study: 33731270
Drug: Oral moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral moxifloxacin 400 mg every 24 h for 7 days
Study: 34512011
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia and multi-modal analgesia (Control Group G)
Study: 32217500
Drug: Mobile Interactive
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile Interactive Supervised Therapy (MIST)
Study: 32809152
Drug: Initial medical
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial medical management (medical treatment based on anticoagulation, delayed by 24 hours if intravenous thrombolysis was performed)
Study: 32603526
Drug: Roxadustat (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (1 mg/kg)
Study: 32603526
Drug: Roxadustat (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (2 mg/kg)
Study: 33545710
Drug: Dose-optimized radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-optimized radiotherapy (DORT)
Study: 32941265
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for ruptured AVMs
Study: 34906127
Drug: Overall sample
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall sample (including treatment and control)
Study: 32509046
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral drugs and weekly paraspinal nerve block in C1 group.
Study: 32509046
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral drugs and weekly paraspinal nerve block in C2 group.
Study: 33518062
Drug: Berberine (BBR)
Normalized name: berberine
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine (BBR) 250 mg/kg
Study: 33518062
Drug: Antibiotic positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic positive control (200 mg/kg oxytetracycline calcium and 250 mg/kg nasiheptide)
Study: 32732773
Drug: Blood flow
Normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood flow restriction therapy on one arm
Study: 32732773
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy on the other arm
Study: 32589648
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg bid for eight weeks
Study: 32589648
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of rifampicin, isoniazid, pyrazinamide and ethambutol
Study: 34984822
Drug: SGLT-2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT-2 inhibitor (empagliflozin)
Study: 35232894
Drug: DA-9701 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-9701 (30 mg, 3 times a day for 4 weeks)
Study: 35101346
Drug: Cetuximab plus
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab plus avelumab (rechallenge therapy)
Study: 33650779
Drug: Liraglutide (0.3–0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (0.3–0.9 mg/day)
Study: 34419277
Drug: Milk replacer
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk replacer mixed with antirotavirus antibodies
Study: 34419277
Drug: Colostrum replacer
Normalized name: COLOSTRUM
DrugBank: Human colostrum (DB19286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colostrum replacer mixed with antirotavirus antibodies
Study: 34346165
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of NL005 (0.05, 0.25, 0.5, 2.0, 5.0, 12.5 or 25.0 μg/kg)
Study: 34346165
Drug: Multiple intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple intravenous doses of NL005 (0.5, 2.0 and 5.0 μg/kg) administered once daily for 10 days
Study: 32989366
Drug: Various factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various factors associated with HPV vaccine hesitancy
Study: 32586143
Drug: On-treatment HDL
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment HDL in the lowest quartile (≤ 1.21 mmol/l)
Study: 32586143
Drug: On-treatment HDL
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment HDL in the second and third quartiles
Study: 32586143
Drug: Baseline HDL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline HDL in the lowest quartile (≤ 1.21 mmol/l)
Study: 32586143
Drug: On-treatment HDL
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment HDL in the lowest quartile
Study: 32586143
Drug: Baseline HDL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline HDL ≤ 1.21 mmol/l
Study: 33420951
Drug: Sorafenib-Pravastatin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib-Pravastatin combination (Arm C)
Study: 34847564
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (group-exercise training once weekly and independent exercises at home twice weekly for 24 weeks)
Study: 36162037
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg once every 2 weeks plus ipilimumab 1 mg/kg once every 6 weeks
Study: 36162037
Drug: Nivolumab 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 480 mg once every 4 weeks
Study: 32461038
Drug: No psychotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No psychotropic drugs
Study: 32461038
Drug: ≥3 psychotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ≥3 psychotropic drugs
Study: 32461038
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of antidepressant agents in mild and moderate dementia
Study: 35995102
Drug: Study cigarettes
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study cigarettes (0.4, 2.4, 15.8 mg/g)
Study: 35995102
Drug: 0.4 mg/g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/g nicotine content
Study: 34283906
Drug: Weekly educational
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly educational SMS for 6 months
Study: 32466811
Drug: Mentalization-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-based treatment plus treatment as usual (MBTp + TAU)
Study: 32284053
Drug: 48 mg
Normalized name: betaine 648 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 mg sucralose
Study: 32284053
Drug: 96 mg
Normalized name: camphor 96 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 96 mg sucralose
Study: 34498314
Drug: Infliximab plus
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab plus thiopurines (combination therapy)
Study: 34498314
Drug: Overall cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall cohort (combination therapy vs. monotherapy)
Study: 32957318
Drug: 10% hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% hypertonic saline (HTS), 0.63 ml/kg, administered as a bolus via a central venous catheter, infused over 15 minutes
Study: 32957318
Drug: 20% mannitol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% mannitol, 2 ml/kg, administered as a bolus via a central venous catheter, infused over 15 minutes
Study: 32508363
Drug: Adjunctive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive therapy with quetiapine or lamotrigine
Study: 32508363
Drug: Monotherapy (lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (lithium or divalproex)
Study: 34181506
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of measles‐mumps‐rubella (MMR) vaccine
Study: 32676780
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g TXA via intravenous injection and 1 g TXA for external use (Group B)
Study: 32676780
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rivaroxaban qd for 35 days after surgery (Group C)
Study: 32676780
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of TXA and rivaroxaban (Group D)
Study: 34365063
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg IM ketorolac
Study: 34365063
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg IM ketorolac
Study: 32380977
Drug: Andrographolide (AP)
Normalized name: Andrographolide
DrugBank: Andrographolide (DB05767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andrographolide (AP) 140 mg orally twice daily for 24 months
Study: 35537503
Drug: Left Atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left Atrial Appendage Occlusion (LAAO) with post-procedural dual antiplatelet therapy (DAPT)
Study: 35537503
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antithrombotic therapy or DAPT as deemed appropriate)
Study: 36878213
Drug: TAK-003 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-003 vaccine
Study: 34504796
Drug: Dabrafenib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabrafenib (150 mg twice daily) plus Trametinib (2 mg once daily)